FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the
Distinguished physicians and investigators in hypertension, cardiovascular diseases, nephrology and innovative cardiovascular trials to advise on the clinical development of RTN-001 FALLS CHURCH, Va.--( BUSINESS WIRE)-- Retension Pharmaceuticals, Inc. (“Retension” or the “Company”), a
Appointments strengthen clinical and regulatory leadership as the Company advances RTN-001 through its Phase 2b trial FALLS CHURCH, Va.--( BUSINESS WIRE)-- Retension Pharmaceuticals, Inc. (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for
Seasoned executives bring deep cardiovascular clinical development experience and financial leadership as RTN-001 advances through Phase 2b clinical testing FALLS CHURCH, Va.--( BUSINESS WIRE)-- Retension Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing RTN-001 for
